Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome.

ABSTRACT: Type 2 diabetic osteoporosis (T2DOP) is a complex metabolic bone disorder characterized by reduced bone density and increased risk of osteoporosis in patients with type 2 diabetes mellitus. The etiology of T2DOP is multifactorial, involving hyperglycemia, insulin resistance, and gut microbiota dysbiosis. Current management strategies for T2DOP typically involve a comprehensive approach, including strict glycemic control, vitamin D and calcium supplementation, anti-osteoporotic medications, increased physical activity, and gut microbiota modulation. This study aimed to investigate the therapeutic potential of the combination of Dasatinib and Quercetin (D + Q), known as senolytics, in treating T2DOP. To elucidate the underlying mechanisms, a well-characterized T2DOP mouse model was establish

SUBMITTER: Yang J 

PROVIDER: S-EPMC12442493 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature